Market Place
Sourcing Support
EMD Serono Presents New MAVENCLAD® Four-Year Data
12 Sep 2024 //
BUSINESSWIRE
Emd Serono Cancer Advances: New Data At Asco 2024 Showcase
23 May 2024 //
BUSINESSWIRE
EMD Serono Presents New MAVENCLAD® Data Supporting Cognitive Function Benefits
29 Feb 2024 //
BUSINESSWIRE
EMD Serono and Takeda Join Rancho as Charter Members of the Spatial Initiative
06 Feb 2024 //
ACCESSWIRE
Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line
22 Jan 2024 //
BUSINESSWIRE
EMD Serono lays out MS therapies` immune-system suppression risks in campaign
17 Jan 2024 //
ENDPTS
EMD Serono Announces Plans for U.S. Healthcare Headquarters in Boston’s District
14 Nov 2023 //
BUSINESSWIRE
EMD Serono`s Biologic GONAL-F (follitropin) Receives Approval in the U.S.
13 Nov 2023 //
FDA
EMD Serono to Present Latest Research from Oncology Portfolio at ESMO 2023
16 Oct 2023 //
BUSINESSWIRE
Evobrutinib, CNS-Penetrant BTKi, Has Shown Sustained Clinical Benefit
11 Oct 2023 //
BUSINESSWIRE
EMD Serono Presents New MAVENCLAD® (Cladribine) Tablets Data
10 Oct 2023 //
BUSINESSWIRE
EMD Serono Launches Collaboration with United Nations-Guided Global Initiative
05 Oct 2023 //
BUSINESSWIRE
EMD Serono`s Biologic Bavencio (Avelumab) Receives Approval in the U.S.
06 Sep 2023 //
FDA
Obesity drugs don`t make WHO`s essential list, but Ebola, MS drugs added
27 Jul 2023 //
REUTERS
EMD Serono Highlights Commitment to Improving Cancer Outcomes at ASCO 2023
25 May 2023 //
BUSINESSWIRE
EMD Serono Highlights New Data for Evobrutinib
26 Oct 2022 //
BUSINESSWIRE
Xevinapant Show Survival Rate Nearly Doubled in with Unresected LA SCCHN
07 Sep 2022 //
BUSINESSWIRE
EMD Serono`s Bavencio (Avelumab) Receives Supplemental Approval in U.S.
15 Jul 2022 //
FDA
Deeming success unlikely, Merck KGaA cuts lung cancer trial
04 Jun 2022 //
FIERCEBIOTECH
EMD Serono to Present Latest Research From Oncology Portfolio at ASCO 2022
26 May 2022 //
BUSINESSWIRE
EMD Serono Shares Advances in MS Portfolio with Efficacy and Safety Data at AAN
31 Mar 2022 //
BUSINESSWIRE
EC Approves TEPMETKO in Advanced NSCLC with METex14 Skipping Alterations
18 Feb 2022 //
BUSINESSWIRE
EMD Serono Launches New Sustainable Slim Pack for Fertility Medication
17 Feb 2022 //
PRNEWSWIRE
EMD Serono Expands Neurology Pipeline with Acquisition of Chord Therapeutics
20 Dec 2021 //
BUSINESSWIRE
New Data Show Dramatic Emotional Toll of Pandemic on Unpaid Caregivers
18 Nov 2021 //
BUSINESSWIRE
Data: Evobrutinib Demonstrates a Significant Reduction in SEL with RMS
14 Oct 2021 //
BUSINESSWIRE
New MAVENCLAD Data Show Sustained Effectiveness and Benefit in RMS Patients
13 Oct 2021 //
BUSINESSWIRE
EMD Serono Completes Enrollment of Evobrutinib Phase III Clinical Trials
04 Oct 2021 //
BUSINESSWIRE
EMD Serono Completes Enrollment of Evobrutinib Phase III Clinical Trials
04 Oct 2021 //
BUSINESSWIRE
EMD Serono to Highlights From Oncology Portfolio at WCLC & ESMO 2021
13 Sep 2021 //
BUSINESSWIRE
Even during pandemic, FDA approvals remain on a rapid pace
07 Jul 2021 //
FIERCEPHARMA
EMD Serono Announces New Data Strengthening Evidence for Continued Safe
23 Apr 2021 //
BUSINESSWIRE
EMD Serono Announces New Data Strengthening Evidence for Continued Safe
22 Apr 2021 //
BUSINESSWIRE
EMD Serono presents data from ph II trial of BTK inhibitor, evobrutinib at AAN
21 Apr 2021 //
PHARMABIZ
Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction
16 Apr 2021 //
BUSINESSWIRE
Real-World Evidence Study at Miami CFAR Suggests HIV-Associated Wasting Remains
09 Feb 2021 //
PRNEWSWIRE
FDA Approves TEPMETKO® as the First and Only Once-daily Oral MET Inhibitor
03 Feb 2021 //
PRNEWSWIRE
EMD Serono`s Biological Avelumab Receives Approval in US
13 Nov 2020 //
FDA
Biogen MA, Inc. v. EMD Serono, Inc. (Fed. Cir. 2020)
30 Sep 2020 //
PATENT DOCS
EMD Serono to Showcase New Data at ACTRIMS-ECTRIMS MSVirtual2020
03 Sep 2020 //
PRNEWSWIRE
FDA Accepts Filing of New Drug Application for Tepotinib for the Treatment
24 Aug 2020 //
PRNEWSWIRE
Enforcement Report - Week of July 15
16 Jul 2020 //
FDA
Health Canada Issues Recall of EMD Serono (A Division of EMD Inc., Canada)` Cetrotide
07 Jul 2020 //
HEALTH CANADA
US approves Bavencio for bladder cancer
30 Jun 2020 //
PHARMATIMES
EMD Serono Initiates First Clinical Trial of TLR7 and 8 Inhibitor as a Treatment
24 Jun 2020 //
PRNEWSWIRE
Rebif® U.S. Label Now Includes Pregnancy Outcomes and Lactation Information
27 May 2020 //
PRNEWSWIRE
New Late-Breaking Data at EAN Indicate Evobrutinib is the First BTK Inhibitor
22 May 2020 //
PRNEWSWIRE
Breakthrough Innovation in Cancer Care From EMD Serono Pipeline to at ASCO 2020
13 May 2020 //
PRNEWSWIRE
Data From EMD Serono at ASCO 2020 to Showcase Significant Clinical Advances
30 Apr 2020 //
PRNEWSWIRE
EMD Serono & Pfizer Receive US FDA Breakthrough Therapy Designation
08 Apr 2020 //
PRNEWSWIRE
Exploratory Analysis Reports Efficacy and Safety of BAVENCIO® (avelumab)
22 Oct 2019 //
PR NEWSWIRE
New data backs Merck’s segue into MS with BTK inhibitor
13 May 2019 //
PR NEWSWIRE
Merck KGaA launches campaign to bring MS insights to life
12 Nov 2018 //
FIERCE PHARMA
Merck KGaA launches campaign to bring MS insights to life
12 Nov 2018 //
FIERCE PHARMA
EMD Serono`s Biological Avelumab Receives Approval in US
24 Oct 2018 //
FDA
Rehan Verjee to Lead EMD Serono as Company Advances Strategy in North America
31 Aug 2018 //
PR NEWSWIRE
FDA Accepts Cladribine Tablets as Potential Treatment for r/r MS
30 Jul 2018 //
PR NEWSWIRE
Merck KGaA, Darmstadt, Germany`s Massachusetts-based`Top Place to Work` Business
17 Nov 2017 //
PR NEWSWIRE
Opdivo° (Nivolumab): Bristol-Myers Squibb V. Emd Serono & Merck Kgaa
26 Jul 2017 //
PATENT LITIGATION
